Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade
- PMID: 6169958
- DOI: 10.1097/00005344-198100031-00004
Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade
Abstract
The hemodynamic pattern in hypertension varies according to the age of the subject and the stage of the hypertensive disorder. In the early stage, both cardiac output and systemic vascular resistance tend to be elevated. Already at that stage, mild degrees of left ventricular function disturbance can be detected. Advanced stages are characterized by a hypokinetic type of circulation with subnormal cardiac output and considerably increased systemic vascular resistance. Both cardioselective and nonselective beta-receptor antagonists lower cardiac output and tend to raise systemic vascular resistance. Even left ventricular filling pressures tend to be higher. While these effects are most distinct in the acute experiment, cardiac output remains always depressed and systemic vascular resistance stabilizes often at a higher level, compared with pretreatment values, even during long-term therapy. The antihypertensive action of beta-receptor blockers appears to be mainly due to the reduction of cardiac output. Combined alpha--beta-adrenergic blockade lowers blood pressure predominantly by alpha-adrenoceptor-mediated reduction of systemic vascular resistance both when induced acutely and during long-term administration. Owing to its beta-adrenoceptor blocking component, the increase of cardiac output is abolished: cardiac output is maintained at pretreatment levels, as is left ventricular filling pressure. Since a well-balanced blockade of both alpha- and beta-adrenergic receptors counteracts the hemodynamic changes occurring in the course of hypertension and tends to restore cardiovascular dynamics towards normal, combined alpha--beta-adrenoceptor blockade appears to be one of the most logical and rational therapeutical approaches to hypertension.
Similar articles
-
Pharmacology of combined alpha-beta-blockade. I.Drugs. 1984;28 Suppl 2:16-34. doi: 10.2165/00003495-198400282-00003. Drugs. 1984. PMID: 6151889 Review.
-
Differential hemodynamic effects of beta-adrenoceptor blockers, Ca antagonists and combined alpha-beta-receptor blockade in ischemic heart disease.Acta Med Scand. 1986;219(1):17-22. doi: 10.1111/j.0954-6820.1986.tb03270.x. Acta Med Scand. 1986. PMID: 2869648 Clinical Trial.
-
Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.Drugs. 1984;28 Suppl 2:35-50. doi: 10.2165/00003495-198400282-00004. Drugs. 1984. PMID: 6151890 Review.
-
Acute effects of combined alpha/beta-adrenoceptor blockade v combined beta-receptor and slow channel calcium blockade in ischemic heart disease complicated by hypertension. Hemodynamic and adrenergic responses.Am J Hypertens. 1991 Aug;4(8):709-13. doi: 10.1093/ajh/4.8.709. Am J Hypertens. 1991. PMID: 1681821
-
Cardiovascular dynamics after acute and long-term alpha- and beta-adrenoceptor blockade at rest, supine and standing, and during exercise.Br J Clin Pharmacol. 1979;8(Suppl 2):101S-105S. Br J Clin Pharmacol. 1979. PMID: 43162 Free PMC article.
Cited by
-
Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.Drugs Aging. 1991 May;1(3):194-211. doi: 10.2165/00002512-199101030-00004. Drugs Aging. 1991. PMID: 1686570 Review.
-
Pharmacology of combined alpha-beta-blockade. I.Drugs. 1984;28 Suppl 2:16-34. doi: 10.2165/00003495-198400282-00003. Drugs. 1984. PMID: 6151889 Review.
-
Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.Cardiovasc Drugs Ther. 1988 Sep;2(3):343-53. doi: 10.1007/BF00054642. Cardiovasc Drugs Ther. 1988. PMID: 2908732 Review.
-
Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist.Int Arch Occup Environ Health. 1985;56(1):41-7. doi: 10.1007/BF00380699. Int Arch Occup Environ Health. 1985. PMID: 2863220 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources